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Purpose: The present study was designed to explore the potential of flunarizine for cisplatin induced painful uremic neuropathy 
in rats. 
Methods: Cisplatin (2 mg/kg; i.p., for 5 consecutive days) was administered and renal uremic markers i.e., serum creatinine were 
estimated on days 4 and 25. Behavioral changes were assessed in terms of thermal hyperalgesia (hot plate, plantar, tail immer-
sion, and tail flick tests at different time intervals). Biochemical analysis of total calcium, superoxide anion, DNA, and transketo-
lase, and myeloperoxidase activity in tissue samples was also performed. Furthermore, flunarizine (100, 200, and 300 µM/kg; 
p.o., for 21 consecutive days) was administered to evaluate its potency on uremic neuropathy, and the results were compared 
with those for the carbamazepine-treated (30 mg/kg; p.o., for 21 consecutive days) groups. 
Results: Flunarizine attenuated the cisplatin-induced uremic neuropathy, and the degree of behavioral and biochemical changes 
in serum and tissue samples in a dose dependent manner. The medium and high doses of flunarizine were shown to produce a 
significant effect on cisplatin induced painful uremic neuropathy. 
Conclusions: Our results indicate the potential of flunarizine for anti-oxidative, anti-inflammatory, and neuroprotective actions. 
Therefore, it may have use as a novel therapeutic agent for the management of painful uremic neuropathy.
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INTRODUCTION
Uremic neuropathy can be defined as an “Abnormal unpleasant 
pain sensation along with central-peripheral axonal damage, 
nerve conduction velocity, and demyelination of the nervous 
system caused by accumulation of uremic toxin in the circula-
tory as well as neuronal system”. The development of potential 
uremic neuropathy, i.e., “dying-back neuropathy” and/or “cen-
tral-peripheral axonopathy” and demyelination is caused by 
uremic toxins such as parathyroid hormone, β2-microglobulin, 
indoxyl sulfate, potassium, inorganic phosphate, and hydrogen 
ion [1]. The kidney plays an important role in the elimination 
of numerous organic anions and cations, including uremic tox-
ins, from the blood into the urine. Clinically, hemodialysis and 
kidney transplantation can contribute to the development of 
neurological complications, and observed mortality in patients 
with uremia [2]. Uremic conditions frequently develop with re-
nal failure and lead to alterations of the central-peripheral ner-
vous system as well as the muscular system. The uremia-in-
duced neuropathic pain progresses over months and has been 
estimated to be present in 60 to 100% of patients on dialysis [1].
  Cisplatin (cis-diamminedichloroplatinum II) is a divalent 
platinum-based chemotherapeutic agent used in the manage-
ment of various types of cancers of vital organs such as the tes-
tis, ovary, bladder, lung, and cervical region [3]. The therapeutic 
effect of cisplatin is dose-dependent. However, clinically, a com-
plete beneficial effect is limited because of the potential for 
nephrotoxic and neurotoxic effects [4]. The nephrotoxic effect 
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of cisplatin is cumulative and dose-dependent, and often re-
quires dose reduction or withdrawal. It is known that cisplatin 
treatment damages the proximal tubules of the kidney by dif-
ferent mechanisms, including oxidative stress, inflammation, 
DNA damage, and apoptosis [5]. Additionally, it has been re-
ported that indoxyl sulfate (a representative of uremic toxin) is 
involved in the progression of cisplatin-induced renal failure 
and neurotoxicity [6]. Uremic neuropathy symptoms are insidi-
ous in onset and consist of a tingling and prickling sensation in 
the legs. Paresthesias are most common and usually the earliest 
symptom. Hyperalgesia is a common symptom of painful ure-
mic neuropathy [7].
  Clinically, flunarizine (a T-type calcium channel antagonist) 
has been widely used for treatment of vertigo, migraine, epilep-
sy, tinnitus, and liver dysfunction [8,9]. Many studies revealed 
that direct inhibition of oxidative stress by flunarizine may be 
the critical mechanism in the protection of cisplatin-induced 
renal toxicity [10]. Moreover, it has also been reported to exert 
the beneficial effects on cisplatin induced neurotoxicity [11]. 
The present study was the first attempt to explore the potential 
of flunarizine for cisplatin-induced painful uremic neuropathy 
in rats. Various drugs are used in the management of neuro-
pathic pain, but few medications are approved by the Food and 
Drug Administration for the management of neuropathic pain. 
One approved drug is carbamazepine, which was approved for 
the treatment of trigeminal neuralgia on the basis of clinical tri-
als [12]. Carbamazepine is an anti-convulsant and mood-stabi-
lizing agent. It has been used for the treatment of epilepsy, bipo-
lar disorder as well as trigeminal neuralgia. It is also used for a 
variety of indications such as attention deficit hyperactivity dis-
order, schizophrenia, phantom limb syndrome, complex region-
al pain syndrome, paroxysmal extreme pain disorder, neuro-
myotonia, intermittent explosive disorder, borderline personal-
ity disorder and post-traumatic stress disorder [13]. Carbam-
azepine was reported to treat platinum induced neuropathic 
pain in human and in rat [14]. Therefore, it was used as a posi-
tive control in the present study. The purpose of this study is to 
investigate the potential effects of flunarizine on cisplatin in-
duced painful uremic neuropathy in rat.
MATERIALS AND METHODS
Animals
Wistar rats of either sex weighing between 180 and 200 g were 
used. Animals were procured from Punjab Agriculture Univer-
sity, Department of Animal Sciences, Ludhiana. They were fed 
a standard laboratory diet and housed at environmental tem-
perature and humidity. A 12-hour natural light and dark cycle 
was maintained throughout the experimental protocol. The an-
imals had free access to standard laboratory chow and water ad 
libitum. The experimental protocol was duly approved by the 
Institutional Animal Ethics Committee and care of the animals 
was carried out as per the guidelines of Committee for the Pur-
pose of Control and Supervision of Experiments on Animals 
(CPCSEA), Ministry of Environment and Forest, Government 
of India (Reg No:- 874/ac/05/CPCSEA).
Drugs and Chemicals
Chemicals such as Folin-Ciocalteu’s Phenol reagent (Merck 
Limited, Mumbai, India), bovine serum albumin (Sisco Re-
search Laboratories Pvt. Ltd., Mumbai, India), nitroblue tetra-
zolium (NBT), deoxyribonucleic acid, and phloroglucinol (SD 
Fine Chemicals, Mumbai, India) were procured for the present 
study. Flunarizine, cisplatin, and carbamazepine were gifts from 
Sun Pharma LTD, Mumbai, India and Ranbaxy Pharmaceuti-
cals, Mumbai, Inidia.
Induction of Uremic Neuropathy
Cisplatin (2 mg/kg of body weight) was administered intraperi-
toneally for 5 consecutive days (days 0 to 4) to induce uremia in 
rats [15]. The development of neuropathic pain was assessed 
from the degree of central and peripheral thermal hyperalgesia 
as assessed by various methods, i.e., hot plate, plantar, tail im-
mersion, and tail flick tests.
Experimental Protocol
The Wistar rats were randomly divided into nine groups (n=6 
in each group). The groups were as follows.
  Group I (Normal control group): Rats were not subjected to 
any drug or vehicle administration and were kept for 19 days.
  Group II (Cisplatin control group): Rats were administered 
cisplatin (2 mg/kg; i.p. for 5 consecutive days) for induction of 
painful uremic neuropathy. 
  Group III (Vehicle in cisplatin treated group): Rats were ad-
ministered to normal saline (5 mL/kg of 0.9 % w/v of sodium 
chloride, p.o.) for 21 consecutive days (from 4 to 25). 
  Group IV (Flunarizine per se): Rats were administered flu-
narizine (300 µM/kg; p.o.) for 21 consecutive days (from 4 to 25). 
  Group V (Carbamazepine per se): Rats were administered 
carbamazepine (30 mg/kg; p.o.) for 21 consecutive days (from 4 www.einj.or.kr    129
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to 25). 
  Groups VI-VIII (Flunarizine in cisplatin treated group): Rats 
were administered flunarizine (100, 200, and 300 µM/kg; p.o.) 
for 21 consecutive days (from 4 to 25). 
  Groups IX (Carbamazepine in cisplatin treated group): Rats 
were administered carbamazepine (30 mg/kg; p.o.) for 21 con-
secutive days (from 4 to 25). 
  The behavioral tests were performed at different time inter-
vals, i.e., days 0, 4, 11, 18, and 25. Blood samples were collected 
on days 4 and 25 for the estimation of creatinine. On day 25, all 
of the animals were killed and tissue samples of the sciatic nerve 
were collected for biochemical analysis.
Behavioral Assessment
Hot plate test
The thermal nociceptive threshold, an index of thermal hyper-
algesia, was assessed by the hot plate test as described by Borta 
and Schwarting [16]. An Eddy’s hot plate (RSCO Scientific 
Equipments, Mumbai, India) was pre-heated and maintained at 
a temperature of 52.5±0.5°C. Rats were placed on the hot plate 
and the nociceptive threshold was assessed with respect to hind 
paw licking. Response was recorded in seconds. A cutoff time 
of 20 seconds was maintained.
Plantar test
Sensitivity of the right hind paw to radiant heat was measured 
under a radiant heat lamp source as described by Hargreaves et 
al. [17]. The intensity of the radiant heat stimulus was maintained 
at 25±0.1°C. Response of paw withdrawal latency was noted in 
seconds. A cutoff time of 15 seconds was maintained.
Tail heat hyperalgesia test
Spinal thermal sensitivity was assessed by the tail immersion 
test as described by Necker and Hellon [18]. Tail heat-hyperal-
gesia was noted with the immersion of the terminal part of the 
tail (1 cm) in water maintained at a temperature of 52.5±0.5°C. 
The duration of the tail withdrawal reflex was recorded, as a re-
sponse of spinal heat sensation and a cutoff time of 15 seconds 
was maintained.
Tail flick test
Spinal thermal sensitivity was assessed by the tail flick test as 
described by D’Amour and Smith [19]. The temperature of the 
heating element (Nichrome wire) of an analgesimeter (Adarsh 
Scientific Industries, Ambala Cantt., India) was maintained at 
52±0.5°C. The tail of the rat was placed on the analgesimeter at 
a uniform distance from the Nichrome wire. The tail flick re-
sponse was noted. A cutoff time of 15 seconds was maintained.
Biochemical Analysis
Blood samples were collected by retro-orbital sinus puncture 
under anesthesia (diethyl ether) at different time intervals (i.e., 
days 4 and 25). Serum samples were prepared for the estima-
tion of uremic marker (i.e., creatinine level) changes in rats. 
Furthermore, the sciatic nerve was removed on day 25 and ho-
mogenized for biochemical analysis of total calcium, superox-
ide anion, DNA, and transketolase and myeloperoxidase activi-
ty. 
 
Assessment of renal function 
Creatinine was estimated in serum samples by use of spectro-
photometric instruments (Spectrochem Instruments Pvt. Ltd., 
Hyderabad, India) with standard diagnostic kits (Span Diag-
nostics, Gujarat, India). Abnormal changes in the creatinine 
level served as an indicator of impairement of glomerular func-
tion and the presence of uremia throughout the study protocol.
Estimation of total calcium
Total calcium levels were estimated in the sciatic nerve as de-
scribed by Severnghaus and Ferrebee [20] and Muthuraman et 
al. [21]. Brieﬂy, the sciatic nerve homogenate was mixed with 1 
mL of trichloroacetic acid (4%) in the ice-cold condition and 
centrifuged at 1,500×g for 10 minutes. The clear supernatant 
was used for estimating the total calcium levels atomic emission 
spectroscopy at A
556 nm. 
Estimation of superoxide anion
The sciatic nerve superoxide anion generation was estimated in 
terms of measuring reduced NBT as described in the method 
of Wang et al. [22]. The absorbance of formazan was determined 
by spectrophotometrically at A
540 nm. 
  The quantity of NBT reduction=A×V/(T×Wt×ε×l),
  Where A is the absorbance of blue formazan at 540 nm, V is 
the volume of the solution, T is the time period (90 minutes) 
during which rings were incubated with NBT, Wt is the blotted 
wet weight of the sciatic nerve, ε is the extinction coefficient of 
blue formazan (i.e., 0.72 L/mM/mm), and l cm is the length of 
the light path. Results are reported as picomoles per minute per 
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Estimation of DNA
  Nucleic acid extraction was performed as described by Sch-
neider [23]. Sciatic nerve DNA was estimated in terms of DNA 
fragmentation as described in the methods of Dische [24] and 
Stumpf [25]. Briefly, the method depends on the production of 
a pink color by the reaction of cysteine and sulfuric acid with 
DNA as an index of DNA fragmentation. Absorbance was de-
termined spectrophotometrically at A
490 nm. 
Estimation of transketolase activity 
Transketolase (EC 2.2.1.1) is a ubiquitous thiamine diphosphate 
(ThDP)-dependent enzyme that plays an important role in the 
oxidative pentose phosphate pathway of virtually all organisms. 
Transketolase activity was assessed in terms of R5P consump-
tion as described by Dische and Borenfreund [26]. Absorbance 
was determined spectrophotometrically at A
510 and A
552 nm 
and subtracted. 
Estimation of myeloperoxidase activity
Myeloperoxidase, an enzyme liberated due to the activation of 
polymorphonuclear leukocytes, is used as an indication of tis-
sue neutrophil accumulation. Myeloperoxidase activity was 
measured by using a procedure similar to that documented by 
Hillegass et al. [27]. The absorbance was determined spectro-
photometrically at A
460 nm for 3 minutes. Myeloperoxidase ac-
tivity was expressed as unit per gram tissue. One unit of myelo-
peroxidase activity was defined as that degrading 1 µM perox-
ide per minute at 25°C.
Estimation of total protein content
The protein concentration was estimated according to the meth-
od of Lowry et al. [28] by using bovine serum albumin as a 
standard. Absorbance was determined spectrophotometrically 
at A
750 nm.
Statistical Analysis
All results were expressed as means±standard deviations (SDs). 
The data for all biochemical variables were statistically analyzed 
by one-way analysis of variance followed by Tukey’s multiple 
range tests by using Sigmastat Version-2.0 software. P<0.05 were 
considered to be statistically significant.
RESULTS
Effect of Flunarizine on Changes in Renal Functional 
Markers
  Cisplatin administration resulted in a significant rise in the 
levels of creatinine on days 4 and 25 compared with the vehicle 
control group (Fig. 1). Administration of flunarizine (100, 200, 
and 300 µM/kg) attenuated the cisplatin-induced changes in 
Fig. 1. Effect of flunarizine on serum creatinine levels on day 4 and day 25. Data in parentheses indicate the dose of flunarizine in µM/
kg. Values are the mean±SD of 6 animals. Statistical values for serum creatinine level F (8, 53)=5743.16, P<0.001. 
a)P<0.05 vs. sham 
control group. 
b)P<0.05 vs cisplatin control group. 
c)P<0.05 vs. carbamazepine treated group.
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creatinine levels in a dose-dependent manner. A significant 
(P<0.05) effect was observed in the groups treated with the 
medium and high doses. Treatment with carbamazepine pro-
duced similar effects. Moreover, the flunarizine and carbamaze-
pine per se treated groups did not show any significant bio-
chemical changes.
Effect of Flunarizine on Behavioral Changes
Cisplatin administration resulted in a significant development 
of thermal hyperalgesia as reflected by decreased paw and tail 
withdrawal latency in the hot plate, plantar, tail immersion, and 
tail flick tests compared with the vehicle control group (Figs. 
2-5). Administration of flunarizine (100, 200, and 300 µM/kg) 
Fig. 2. Effect of flunarizine on the hot plate test. Data in paren-
theses indicate the dose of flunarizine in µM/kg. Values are the 
mean±SD of 6 animals. Statistical values for hot plate test F (8, 
53)=186,047; P<0.001. 
a)P<0.05 vs. sham control group. 
b)P
<0.05 vs. cisplatin control group. 
c)P<0.05 vs. carbamazepine 
treated group.
Fig. 3. Effect of flunarizine on the plantar test. Data in parenthe-
ses indicate the dose of flunarizine in µM/kg. Values are the 
mean±SD of 6 animals. Statistical values for plantar test F (8, 
53)=173.103; P<0.001. 
a)P<0.05 vs. sham control group. 
b)P
<0.05 vs. cisplatin control group. 
c)P<0.05 vs. carbamazepine 
treated group.
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Fig. 4. Effect of flunarizine on the tail immersion test. Data in 
parentheses indicate the dose of flunarizine in µM/kg. Values 
are the mean±SD of 6 animals. Statistical values for tail immer-
sion test F (8, 53)=125.083; P<0.001. 
a)P<0.05 vs. sham control 
group. 
b)P<0.05 vs. cisplatin control group. 
c)P<0.05 vs. carba-
mazepine treated group.
Fig. 5. Effect of flunarizine on the tail flick test. Data in paren-
theses indicate the dose of flunarizine in µM/kg. Values are the 
mean±SD of 6 animals. Statistical values for tail flick test F (8, 
53)=216.037; P<0.001. 
a)P<0.05 vs. sham control group. 
b)P
<0.05 vs. cisplatin control group. 
c)P<0.05 vs. carbamazepine 
treated group.
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attenuated the cisplatin-induced behavioral changes in a dose-
dependent manner. A significant (P<0.05) effect was observed 
in the groups treated with the medium and high doses. Treat-
ment with carbamazepine produced similar effects. Moreover, 
the flunarizine and carbamazepine per se treated groups did not 
show any significant behavioral changes.
Effect of Flunarizine on Tissue Biochemical Changes 
Cisplatin administration resulted in a significant rise in the level 
of tissue total calcium, superoxide anion, deoxyribonucleic acid, 
transketolase, and myeloperoxidase activity compared with the 
vehicle control group (Table 1). Administration of flunarizine 
(100, 200, and 300 µM/kg) attenuated the cisplatin-induced tis-
sue biochemical changes in a dose-dependent manner. A sig-
nificant (P<0.05) effect was observed in the groups treated 
with medium and high doses. Treatment with carbamazepine 
produced similar effects. Moreover, the flunarizine and carba-
mazepine per se treated groups did not show any significant ef-
fect on tissue biochemical changes.
DISCUSSION
In the present study, cisplatin (2 mg/kg; i.p. for 5 consecutive 
days) administration produced the development of uremia (i.e., 
rise in level of creatinine), decreases in paw and tail withdrawal 
latency (central-peripheral thermal hyperalgesia), and tissue 
biochemical changes, such as in total calcium, superoxide an-
ion, DNA, and transketolase and myeloperoxidase, activity in 
rats. Flunarizine and carbamazepine attenuated the cisplatin-
induced behavioral and biochemical alterations. Previous stud-
ies revealed that cisplatin can cause nephro-, neuro-, hepato-, 
cardio-, and ototoxicity in humans and animals [4,29]. Cisplat-
in has also been reported to induce the uremic condition in ex-
perimental research [15]. Various uremic toxins play a major 
role in the pathogenesis of disease including neuropathic pain 
[1,6]. 
  The most important hypothesis of our study explains that 
cisplatin-induced neurotoxicity is caused by enhancement of 
uremic toxin accumulation which leads to free radical genera-
tion, calcium overload, DNA breakdown, and alteration of 
transketolase and myeloperoxidase activity associated with in-
creased peripheral as well as central neuropathic pain sensation 
i.e., paw and tail withdrawal latency against conduction and ra-
diant heat stimuli in rat. These changes have also been observed 
in various types of neuropathic pain [30] including in our earli-
er findings [21,31-33]. The production of oxidative stress by the 
generation of free radicals (reactive oxygen and reactive nitro-
gen species) along with calcium accumulation plays a major 
role in the pathogenesis of neuropathy as well as in other dis-
eases [32,33]. Cisplatin has been reported to induce oxidative 
stress via free radical generation, lipid peroxidation, and calci-
um accumulation in the uremic condition [10]. Clinical and 
preclinical reports of cisplatin treatment have shown that the 
production of oxidative stress, enzymatic changes and DNA 
breakdown leads to inflammation of the renal and nervous sys-
tem under in the uremic condition [34,35]. 
Table 1. Effect of flunarizine on tissue biomarker changes 
Group
Total calcium 
(ppm/mg of protein)
Superoxide anion 
(pM/mg of protein)
DNA  
(µg/mg of protein)
Transketolase activity  
(nM/min/mg of protein)
Myeloperoxidase activity 
(U/min/mg of protein)
I 3.64±1.06 3.54±0.98 41.31±1.36 156.18±4.62 11.64±1.51
II 34.81±1.26
a) 22.37±1.23
a) 85.12±1.04
a) 89.46±2.71
a) 164.24±3.89
a)
III 35.27±0.94
a) 21.64±1.41
a) 83.83±0.94
a) 87.19±1.94
a) 161.63±4.01
a)
IV 3.52±0.89 3.72±1.03 40.09±1.13 157.32±3.39 11.94±1.09
V 3.59±1.32 3.61±0.99 42.15±1.09 159.54±4.91 12.08±0.92
VI 29.83±1.08
a),c) 17.83±1.24
a),c) 76.05±1.64
a),c) 96.37±2.56
a),c) 139.63±3.53
a)
VII 10.17±1.13
b) 8.32±0.96
b) 48.41±0.96
b) 139.88±2.95
b) 53.73±3.92
b)
VIII 7.94±1.52
b) 4.82±1.35
b) 42.18±1.31
b) 147.73±3.43
b) 38.65±3.36
b)
IX 4.18±0.86
b) 3.42±1.04
b) 39.71±1.06
b) 151.37±3.71
b) 24.62±1.14
b)
Values are presented as mean±SD of 6 animals. 
Statistical values for total calcium F (8, 53)=436524.7, P<0.001; for superoxide anion F (8, 53)=3517.4, P<0.001; deoxyribonucleic acid (DNA) F (8, 
53)=29463.1, P<0.001; for transketolase activity F (8, 53)=156839.08, P<0.001, and for myeloperoxidase activity F (8, 53)=3684.2, P<0.001.
a)P<0.05 vs. sham control group. 
b)P<0.05 vs. cisplatin control group. 
c)P<0.05 vs. carbamazepine treated group.www.einj.or.kr    133
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  In the present study, cisplatin administration appeared to in-
duce behavioral changes as well as biochemical changes. More-
over, these results were obtained under the uremic condition in 
rats, i.e., according to the index of creatinine levels in blood 
samples. However, flunarizine (T-type calcium channel antago-
nist) treatment was shown to reduce such neuropathic pain de-
velopment along with amelioration of the biochemical changes. 
Our earlier findings also suggested that flunarizine has a poten-
tial role in the regulation of cellular calcium, free radical gener-
ation, and alteration of the uremic condition via the modula-
tion of membrane permeability transition pore activation in 
rats [10]. Flunarizine is known to possess free radical scaveng-
ing activity via closing of calcium channels [36]. Calcium-in-
duced activation of calpain (calcium binding protein) and gen-
eration of free radicals from mitochondria play a major role in 
the development of neuropathic pain and axonal degeneration 
[21,31-33]. In the present study, flunarizine was found to have 
ameliorative effect on cisplatin induced painful uremic neurop-
athy in rats which was comparable to that of carbamazepine. 
Therefore, it may serve as potential therapeutic agent for the 
management of uremic neuropathy due to its potential anti-ox-
idant, anti-inflammatory, neuro and nephroprotective actions. 
However, the elaborative studies are required to explore the 
molecular mechanism, in the management of uremic neuropa-
thy. 
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